Larimar Therapeutics (LRMR) Capital Expenditures Growth (5y) (2018 - 2025)
Larimar Therapeutics (LRMR) Capital Expenditures Growth (5y) (2018 - 2025) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.71% |
| Sep 30, 2025 | -92.45% |
| Jun 30, 2025 | 7.54% |
| Mar 31, 2025 | -74.11% |
| Dec 31, 2024 | 56.61% |
| Sep 30, 2024 | 39.08% |
| Jun 30, 2024 | -43.10% |
| Mar 31, 2024 | 56.87% |
| Dec 31, 2023 | 10.07% |
| Sep 30, 2023 | 14.59% |
| Jun 30, 2023 | -13.65% |
| Mar 31, 2023 | -51.57% |
| Dec 31, 2022 | -16.92% |
| Sep 30, 2022 | -65.72% |
| Jun 30, 2022 | 75.89% |
| Mar 31, 2022 | -16.00% |
| Sep 30, 2021 | -20.45% |
| Jun 30, 2021 | 16.83% |
| Mar 31, 2021 | -3.72% |
| Dec 31, 2020 | -14.80% |